首页|期刊导航|药学研究|GLP-1受体激动剂长效制剂的研究进展

GLP-1受体激动剂长效制剂的研究进展OA

Current status of long-acting GLP-1 receptor agonists development

中文摘要英文摘要

肥胖与糖尿病已成为全球范围内代谢性疾病防控的重大挑战.天然胰高血糖素样肽-1(GLP-1)循环半衰期极短,必须经长效化改造方可实现临床应用.本文系统综述了 GLP-1 受体激动剂(GLP-1 RAs)长效制剂的研究进展:在分子结构修饰层面,重点介绍基于白蛋白亲和力的脂肪酸链修饰、分子尺寸扩增及基于受体药理学的优化策略;在制剂策略层面,梳理聚乳酸-羟基乙酸共聚物(PLGA)微球、原位凝胶、脂质载体等递送系统的应用现状与发展趋势.最后总结了现有长效化技术的优势与瓶颈,并对 GLP-1 RAs 长效制剂的未来研发方向与临床转化路径进行了展望.

Obesity and diabetes have emerged as major global challenges in the prevention and control of metabolic diseases.Native glucagon-like peptide-1(GLP-1)possesses an extremely short circulating half-life,necessitating long-acting modifications to enable its clinical application.This review systematically summarized recent advances in long-acting GLP-1 receptor agonists(GLP-1 RAs).At the molecular structural modification level,we focus on fatty acid chain conjugation for albumin affinity,molecular size expansion,and optimization strategies based on receptor pharmacology.At the formulation strategy level,we outline the current applications and development trends of delivery systems such as PLGA microspheres,in situ gels,and lipid carriers.Finally,we summarize the advantages and bottlenecks of existing long-acting technologies and provide perspectives on future research directions and clinical translation pathways for long-acting GLP-1 RA formulations.

张圣雯;何东升;涂家生

中国药科大学药学院药用辅料及仿创药物研发评价中心,江苏 南京 210009中国药科大学药学院药用辅料及仿创药物研发评价中心,江苏 南京 210009中国药科大学药学院药用辅料及仿创药物研发评价中心,江苏 南京 210009

医药卫生

胰高血糖素样肽-1受体激动剂2型糖尿病肥胖长效化策略

GLP-1 RAsType 2 diabetes mellitusObesityLong-acting strategies

《药学研究》 2026 (8)

895-903,9

国家自然科学基金项目(No.82003293)

10.13506/j.cnki.jpr.2026.08.009

评论